4.5 Article

The influence of genetic variants in SORL1 gene on the manifestation of Alzheimer's disease

Journal

NEUROBIOLOGY OF AGING
Volume 36, Issue 3, Pages -

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1016/j.neurobiolaging.2014.12.007

Keywords

Alzheimer's disease; SORL1; Endophenotypes; SNPs

Funding

  1. German Federal Ministry for Education and Research [01GI0422]
  2. Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health grant) [U01 AG024904]
  3. DOD ADNI (Department of Defense award) [W81XWH-12-2-0012]
  4. National Institute on Aging
  5. National Institute of Biomedical Imaging and Bioengineering
  6. Alzheimer's Association
  7. Alzheimer's Drug Discovery Foundation
  8. BioClinica
  9. Biogen Idec Inc
  10. Bristol-Myers Squibb Company
  11. Eisai Inc
  12. Elan Pharmaceuticals, Inc
  13. Eli Lilly and Company
  14. F. Hoffmann-La Roche Ltd
  15. Genentech
  16. GE Healthcare
  17. Innogenetics
  18. IXICO Ltd.
  19. Janssen Alzheimer Immunotherapy Research & Development, LLC
  20. Johnson & Johnson Pharmaceutical Research& Development LLC
  21. Medpace, Inc
  22. Merck Co, Inc
  23. Meso Scale Diagnostics, LLC
  24. NeuroRx Research
  25. Novartis Pharmaceuticals Corporation
  26. Pfizer Inc
  27. Piramal Imaging
  28. Servier
  29. Synarc Inc
  30. Takeda Pharmaceutical Company
  31. Canadian Institutes of Health Research
  32. Alzheimer Nederland
  33. Stichting VUmc fonds

Ask authors/readers for more resources

We studied the association of SORL1 single-nucleotide polymorphisms genotypes with measures of pathology in patients with probable Alzheimer's disease (AD) using an endophenotype approach. We included (1) 133 patients from the German Dementia Competence Network (71 +/- 8 years; 50% females; Mini Mental State Examination [MMSE], 24 +/- 3); (2) 83 patients from the Alzheimer's Disease Neuroimaging Initiative (75 +/- 8 years; 45% females; MMSE, 24 +/- 2); and (3) 452 patients from the Amsterdam Dementia Cohort 66 +/- 8 years; 47% females; MMSE, 20 +/- 5). As endophenotype markers we used cognitive tests, cerebrospinal fluid (CSF) biomarkers amyloid-beta, total tau (tau), tau phosphorylated at threonine 181, and hippocampal atrophy. We measured 19 SORL1 SNP alleles. Genotype-endophenotype associations were determined by linear regression analyses. There was an association between rs2070045-G allele and increased CSF-tau and more hippocampal atrophy. Additionally, haplotype-based analyses revealed an association between haplotype rs11218340-A/rs3824966-G/rs3824968-A and higher CSF-tau and CSF-tau phosphorylated at threonine 181. In conclusion, we found that SORL1 SNP rs2070045-G allele was related to CSF-tau and hippocampal atrophy, 2 endophenotype markers of AD, suggesting that SORL1 may be implicated in the downstream pathology in AD. (C) 2015 Elsevier Inc. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available